CompletedPhase 2

Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet

South Korea250 participantsStarted 2018-01-16

Plain-language summary

To Evaluate the Efficacy and Safety of CKD-495

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Male or Female subjects aged ≥ 19
✓. Acute or Chronic gastritis patients who have more than 1 erosion on endoscopy within 7days prior to the use of the Investigator's Product taken date
✓. Patients who have more than 1 subjective symptom

✕. Patients with peptic ulcer, gastroesophageal reflux disease, malignant tumor in the digestive system or coagulation disorder, or taking antithrombotic medicine
✕. Patients who have been taken any gastritis medicine that could affect the treatment: H2 receptor antagonist, PPI(Proton Pump Inhibitor), antacid, improvement of movement in digestive system, Prostaglandin, and protective agent for gastritis
✕. Patients who have to take medicine that could cause gastritis

Improvement rate of gastric erosion

Timeframe: 14days after drug administrations

NCT IDNCT03437785

SponsorChong Kun Dang Pharmaceutical

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2018-10-12